|
|
|
|
 |
Corporate Profile
Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage drug development company specialized in oncology and endocrinology.
Contact us:
Æterna Zentaris Inc.
1405 du Parc-Technologique Blvd.
Québec, Québec
Canada
G1P 4P5
Phone: (418) 652-8525
Fax: (418) 652-0881
www.aezsinc.com
|
 |
|
|
Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with... more...>
Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom’s Macroglobulinemia more...>
|
 |
|
December 7, 2009
Phase 3 trial results for cetrorelix in BPH
More |
|
|
Download PDF (67K) |
| Download and install Acrobat Reader 6.0. |
|
|
|
